Inhibiting Autophagy During Interleukin 2 (IL-2) Immunotherapy
Promotes Long Term Tumor Regression

Xiaoyan Liang¹, Michael E. De Vera¹, William J. Buchser¹, Antonio Romo de Vivar Chavez¹, Patricia Loughran¹,², Donna Beer Stolz², Per Basse³, Tao Wang⁴, Bennett Van Houten⁴, Herbert J. Zeh¹, and Michael T. Lotze¹,³

¹Department of Surgery, University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Pittsburgh PA, 15213
²Center for Biologic Imaging, University of Pittsburgh
³Department of Immunology
⁴UPCI Molecular and Cellular Biology Program, University of Pittsburgh

Running Title: Inhibition of IL-2 Induced Autophagy Prolongs Survival

Precis: The preclinical study shows how the inexpensive autophagy inhibitor chloroquine might be repositioned to greatly enhance the antitumor effects of IL-2, a central growth and survival factor for T cells used for melanoma treatment, while limiting the toxicity that has restricted its broad use in clinic.

Keywords: Autophagy, Interleukin 2, HMGB1, oxidative phosphorylation, tumor metabolism, apoptosis

Fiscal support: UPCI Cancer Center Support Grant, NIH 5P30 CA47904 (Nancy E. Davidson); NIH 1 P01 CA 101944 (Michael T. Lotze)

Corresponding Authors:
1. Michael T Lotze, MD or Xiaoyan Liang MD. PhD
5117 Centre Ave Room G.27
Pittsburgh Pa, 15232
412-623-1211, 412-623-1212
lotzemt@upmc.edu
liangx@upmc.edu

2. Michael E. De Vera MD
Current address:
25865 Barton Rd Suite 101
Transplantation Institute
Loma Linda University
Loma Linda, CA. 92354
909-558-3650
medevera@llu.edu

Conflict of Interest: None
Conventions: IL-2, HMGB1, LC3, OXPHOS
Abstract:

Administration of high dose interleukin 2 (HDIL-2) has durable antitumor effects in 5-10% patients with melanoma and renal cell carcinoma. However, treatment is often limited by side effects, including reversible, multi-organ dysfunction and characterized by a cytokine-induced ‘systemic autophagic syndrome’. Here we hypothesized that the autophagy inhibitor chloroquine (CQ) would enhance IL-2 immunotherapeutic efficacy and limit toxicity. In an advanced murine metastatic liver tumor model, IL-2 inhibited tumor growth in a dose-dependent fashion, and these anti-tumor effects were significantly enhanced upon addition of CQ. The combination of IL-2 with CQ increased long term survival, decreased toxicity associated with vascular leakage, and enhanced immune cell proliferation and infiltration in the liver and spleen. HDIL-2 alone increased serum levels of IFN-γ, IL-6 and IL-18 and also induced autophagy within the liver and translocation of HMGB1 from the nucleus to the cytosol in hepatocytes, effects that were inhibited by combined administration with CQ. In tumor cells, CQ increased autophagic vacuoles and LC3-II levels inhibited oxidative phosphorylation and ATP production and promoted apoptosis, which was associated with increased Annexin V+/PI- cells, cleaved-PARP, cleaved-caspase 3, and cytochrome C release from mitochondria. Taken together, our findings provide a novel clinical strategy to enhance the efficacy of HDIL-2 immunotherapy for cancer patients.
Introduction

Two decades ago, recombinant interleukin 2 received FDA approval for the treatment of patients with advanced renal cancer and subsequently of patients with melanoma. High dose IL-2 (HDIL-2) administration is associated with an objective 25% response rate in patients with kidney cancer, as reported in the recently completed IL-2 SELECT trial (1). Almost 20% of these patients survive more than 5 years (2-4). Attempts to improve the response rate and/or limit toxicity of IL-2 administration by inhibiting TNF, iNOS, or VEGF have failed. Combination with IFN-α administration did not improve outcome appreciably (2, 3). Other efforts including vaccination (5), adoptive cellular therapies (6) and CTLA-4 inhibition (7, 8) are associated with both increased efficacy and toxicity. HDIL-2 administration remains the only agent with proven efficacy in producing durable complete and partial responses in patients with metastatic renal cell carcinoma (RCC) (9).

The greatest limitation of IL-2 treatment has been the associated side effects including hypotension as well as cardiac, gastrointestinal, renal, cerebral, pulmonary, and hepatic toxicity. These adverse effects are occasionally life threatening, and treatment is usually restricted to specialized centers, often resulting in early discontinuation or interruption of treatment (10, 11). The precise mechanism mediating these side effects has not been clear. We have proposed that IL-2 toxicity is due to a cytokine-induced ‘systemic autophagic syndrome’. Recently, several cytokines including Type II interferon and transforming growth factor beta (TGFβ) have been shown to induce autophagy (12). We hypothesized that the systemic syndrome associated with IL-2 treatment was related to cytokine-induced autophagy and temporally limited tissue dysfunction. The use of the autophagy inhibitor, chloroquine (CQ) could limit toxicity and thereby enhance efficacy.

Autophagy is a tightly regulated catabolic process involving the degradation of cellular components through the lysosomal machinery and plays a central role in cell growth, development and homeostasis (13). The role of autophagy in cancer is complex and context dependent. In normal tissues, autophagy is an important tumor suppressor pathway that limits oxidative stress and tissue damage that can promote cancer initiation during periods of excessive
apoptotic cell death and inflammation. Autophagy, however, also supports cellular metabolism that has the potential to aid the growth of advanced tumors with increased metabolic demands following an ‘autophagic switch’ (14) in developing tumors. In an established tumor, cells are exposed to perpetual hypoxia, acidosis and nutrient deprivation. Increased autophagic flux enables adaptation to the hypoxic and nutrient-limited microenvironment. Increased autophagy is observed clinically in late-stage colon cancer, breast cancer, melanoma, hepatoma and malignant glioma (15-19). Enhanced immune responses to tumors have been observed when hypoxia-induced autophagy is inhibited by chloroquine treatment (20). Autophagy promotes metastasis in some circumstances, enhancing tumor cell fitness in response to environmental stress (21).

Several studies have suggested that autophagy may act as a protective mechanism in tumor cells in which cell death is induced by chemotherapy, immunotherapy, or radiotherapy (20, 22-25). Targeting autophagy has increased the antitumor effects of individuals anticancer therapies in preclinical trials (13). There has been very limited exploration of autophagy inhibition therapy in combination with biologic therapy (20, 26).

Chloroquine (CQ) was used for many years as an anti-malarial but is now used most commonly in patients with rheumatoid arthritis and systemic lupus erythematosus. It inhibits autophagy by blocking acidification of the lysosome, preventing fusion with the autophagosome (23). This results in decreased degradation of autophagosomes, eventuating in either apoptotic or necrotic cell death. CQ has extensive biological effects, inhibiting cellular proliferation and/or inducing cell apoptosis in human and murine tumor cell lines (24, 27). Induction of apoptosis is associated with the loss of mitochondrial membrane potential, release of cytochrome c, activation of caspase-9 and caspase-3, and cleavage of poly(ADP-ribose) polymerase. In vivo, CQ significantly inhibits 4T1 colorectal cancer growth and metastasis in murine models and induces apoptosis within the tumor micro-environment (28). Studies of human (24, 29) and murine cancer cell lines (30) suggest that CQ may exert significant antitumor activity by inhibiting the induction of autophagy following cancer therapy. We hypothesized that inhibition of autophagy with CQ in combination with HDIL-2 treatment would
increase antitumor effects and promote survival when compared with IL-2 administration alone, enabling more effective expansion and function of immune cells.

MATERIALS AND METHODS

Animals and Tumor Cell Lines

Female C57BL/6 (B6, H-2b) mice, 8-10 weeks old, were purchased from Taconic (Germantown, NY). Animals were maintained in a specific pathogen-free facility at the University of Pittsburgh Cancer Institute, and used in accordance with institutional and National Institutes of Health guidelines. MC38 murine colorectal carcinoma and Panc-02 adenocarcinoma cells (C57BL/6 syngeneic) were purchased from The American Type Culture Collection (ATCC). RENCA renal cell cancer and B16 melanoma cell lines were gifts from Dr. W. Storkus at the University of Pittsburgh. All these cell lines were authenticated using genomic profiling in March 2012 (IDEX Radil Cell Check, MO). Cells were maintained in DMEM medium supplemented with 5% heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 0.1 mM nonessential amino acids, and 1 mM sodium pyruvate.

Liver Metastasis Model

Liver metastases were obtained by direct portal injection of tumor cells as described previously (31). Briefly, mice were anesthetized with a single intraperitoneal injection of Ketamine (50 mg/kg, NLS animal Health, Owing Mills, MD) and Xylazine (10 mg/kg, NLS animal Health, Owing Mills, MD). The portal vein was exposed through a small midline incision. 2 x 10^5 luciferase transfected tumor cells suspended in 200 µl normal saline (NS) were injected. The incision is closed with vycryl suture. Seven days following tumor inoculation, mice were randomized into 6 groups and received their first bioluminescence imaging (BLI) measurement, then started receiving intraperitoneal injection of rIL-2 with or without combination of CQ. Clinical grade rIL-2 was a kind gift of Prometheus
Laboratories Inc. (San Diego, CA, USA). Untreated control mice (UT) were injected with a comparable amount of NS on the same schedule. Tumor burden was assessed with the IVIS bioluminescence image described below. Blood was collected by direct intracardiac puncture and spleens and livers were harvested for electron microscopy, confocal imaging, and isolation of immune cells.

**Luciferase Transfection of Tumor Cells and Bioluminescence Imaging (BLI)**

Stably transduced tumor cells expressing the firefly luciferase gene were generated by lentiviral transfection of the pGL4 Luciferase Reporter Vector (Promega, Madison) and selected with puromycin. Growth characteristics and phenotype of the transfected cells were compared with the parental strain in vitro to verify the absence of any effects secondary to retroviral insertion. Prior to imaging, mice were anesthetized by Isoflurane (Wester Veterinary, Sterling, MA) inhalation followed by intraperitoneal injection of luciferin (300 mg/kg, Caliper Life Sciences, Hopkinton, MA). After waiting 8 minutes to allow proper distribution of luciferin, the mice were imaged using an IVIS 200 system (Xenogen Corporation, Hopkinton, MA) according to the manufacturer’s instructions. Living Image software (Xenogen) was used to analyze the resultant data. Regions of interest were manually selected and quantification is reported as the average of photon flux within regions of interest. The BLI signal is represented as photons/second/cm²/steradian.

**Isolation of Non-parenchymal Cells and Flow Cytometry**

Mouse livers were mashed and digested 1% collagenase (Sigma, St. Louis, MO) solution at 37°C for 30 minutes. To obtain adequate numbers of non-parenchymal cells, livers from three to five animals were combined from each treatment group. The non-parenchymal cells were then isolated by centrifugation over a Percoll gradient (Sigma Chemical Co., St Louis, MO). Cell surface antigen expression was analyzed by flow cytometry (Becton Dickinson FACScan) using FITC or PE conjugated monoclonal antibodies against mouse CD11c, CD14, CD19, CD4, CD8, Gr-1, and NK1.1 (all from BD Pharmingen, San Diego,
Appropriate isotype and species-matched irrelevant monoclonal antibodies were used as controls.

**Serum Cytokine Determination**

Blood was collected from direct intracardiac puncture at individual intervals following tumor inoculation. Serum was used to measure HMGB1 (Shinotest, Japan), IL-6, IL-18, and IFN-γ (R&D, Minneapolis, MN) levels by ELISA.

**Detection of Apoptosis**

MC38 tumor cells (2 x 10^6 /ml) were cultured in 24-well plates and treated with CQ for 4 or 24 hours. Cells were then harvested and stained with Annexin V and propidium iodide (PI) (BD Pharmingen) according to the manufacturer's protocol. Quantitative analysis was performed by flow cytometry, with 10,000 events acquired from each sample.

**Immunofluorescence Staining**

A portion of each lobe of the liver was embedded in OCT Compound (Miles, Elkhart, IN), frozen, and stored at -80°C. Cryostat sections (8 µm) were used for immunofluorescence evaluation. In vitro, tumor cells were cultured in eight-chamber slides, treated with 100 to 200 µM CQ for 4 and 24 hours, fixed with 2% PFA 30 minutes, and prepared for immunofluorescence staining. The following primary monoclonal antibodies were used: rabbit anti-human HMGB1 (R&D) and rabbit anti-LC3 (Novus Biologicals Inc. CO), rabbit-TOM-20 and mouse anti-cytochrome C (Santa Cruz Biotechnology Inc, Santa Cruz, CA). Slides were incubated with the primary antibody overnight at 4°C. Following three washes in PBS, slides were incubated with fluorescent-conjugated secondary antibodies for 45 minutes followed by Hoechst nuclear staining. Negative controls included staining with the corresponding isotype for each antibody and staining with
secondary antibody alone. Positive controls included immunostaining of known positive tissues.

**Protein Blot Analysis**

Whole-cell lysates were resolved on 10% SDS-PAGE gel and transferred to 0.2 μm nitrocellulose membranes. After blocking, membranes were incubated overnight at 4°C with primary antibodies specific for cleaved-PARP (Cell Signaling, Danvers, MA), caspase-3, (Assay designs Inc, Ann Arbor, MI), LC-3 (Novus Biologicals, CO), cytochrome C (Santa Cruz, Santa Cruz, CA), and β-actin (Sigma, St Louis, MO). After incubation with peroxidase-conjugated secondary antibodies for 1 h at 25°C, membranes were developed with the SuperSignal West Pico chemiluminescence kit (Pierce, Rockford, IL) and exposed to film. Image J was used to quantify the bands.

**Statistical Analyses**

Statistical significance was assessed using the Student's t-test, Mann-Whitney U test, or ANOVA when appropriate using SPSS 16.0 (SPSS, Chicago, IL) or Spotfire DecisionSite (Tibco, Palo Alto, Ca). A p-value < 0.05 was considered significant. All experiments reported here were repeated at least two or three times with similar results with representative findings presented.

Transmission electron microscopy (TEM)(32, 33), ATP Quantification, and XF Bioenergetic Assay were used and are described in supplemental materials.

**Results:**

**Chloroquine, in combination with HDIL-2, promotes profound anti-tumor effects, enhancing murine survival in a liver metastasis model.**

In preliminary experiments, we confirmed that rIL-2 inhibited tumor growth in a dose dependent fashion (Supplemental Figure 1) in a murine liver metastasis tumor model that we have developed. Although administration of
600,000 IU/mouse rIL-2 twice a day can inhibit tumor growth, many of these mice subsequently progress (Figure 1A and B). Administration of high dose rIL-2 results in life-threatening systemic toxicity which precluded administration of higher doses. We hypothesized that these adverse effects may be related to the widespread induction of systemic autophagy. Therefore, we sought to determine the effects of administration of autophagy inhibitor agent CQ both alone and in combination with IL-2, in a hepatic metastatic tumor model.

Mice received 2X10^5 luciferase-labeled mouse colorectal cancer MC38 cells via portal vein injection. Seven days later, they were randomly divided into 6 groups that received vehicle control (UT), CQ alone 50mg/kg/day for 30 days, rIL-2 60,000 (low dose IL-2, LDIL-2) or 600,000 IU/mouse (HDIL-2), twice a day for 5 days, with or without combination of CQ. Tumor growth was measured by BLI (Figure 1A and B) and survival of mice was determined (Figure 1D and Table 1). We found that 50mg/kg CQ alone only had a modest but insignificant effect in inhibiting tumor growth (p=0.44). In the UT control group, median survival was 31 days and the longest survival time was 55 days. IL-2 administration inhibited tumor growth in a dose dependent manner. Low dose IL-2 only modestly inhibited, while HDIL-2 significantly inhibited tumor growth, prolonging the resultant survival time (p<0.01). The median survival in the HDIL-2 group was 135 days and 44.4% of animals were tumor free, surviving longer than 150 days.

A dramatic effect on tumor growth was noted when CQ was administered in combination with HDIL-2. Although BLI revealed visible tumors in all five mice on day 7 prior to treatment in the liver (Figure 1A and B), after 5 days of HDIL-2 and CQ combination treatment, only one mouse developed tumor while the others were completely eradicated (90% of animals) and survived without tumor for over 150 days (Table 1). Comparing the survival curves in these two groups reveals a significant difference (p=0.024). These results suggest that the combination strategy of HDIL-2 and CQ was extraordinarily effective with almost complete elimination of tumors (Figure 1A). Similar anti-tumor effects of IL-2 were observed with treatment of the pancreatic cancer cell line Panc02 in the hepatic tumor model (Supplemental Figure 2) as well as the Renca tumor in Balb/c mice (Supplemental Figure 3). The B16 melanoma pulmonary
metastases model was not susceptible to IL-2 alone (as shown previously by us and others) or in combination with CQ (data not shown).

In the clinic, one of the primary adverse effects of HDIL-2 therapy is the vascular leak syndrome resulting in fluid retention associated with increased body weight. In order to assess HDIL-2 toxicity, murine body weight was measured before and every other day during treatment. Although handling of mice receiving saline control typically is associated with initial weight loss, administration of HDIL-2 increased body weight, and this effect was prevented by combination with CQ (p<0.05) (Figure 1C). Serum chemistry analysis suggested that 600,000IU IL-2 twice a day did not result in significant liver or kidney dysfunction (Supplemental Table 1), unlike that observed in patients.

**HDIL-2 administration induces inflammatory cytokine release which is inhibited by CQ.**

Our previous findings indicated that HMGB1 plays an important role in regulation of autophagy and apoptosis in tumor cells. Translocation from the nucleus into the cytosol is associated with release of HMGB1 into the serum (33). Systemic release of HMGB1 may be related to the induction of systemic autophagy within tissues or cells which are in turn associated with the toxicity of HDIL-2. We assessed HMGB1 distribution in situ in the liver as well as its serum level. Two hours following the last the dose of HDIL-2 treatment (day 12 following tumor inoculation), liver tissues and serum were harvested. HMGB1 distribution in vivo, and liver tissue immunofluorescence staining showed that HMGB1 was present predominately in the nuclei of hepatocytes in untreated animals, as we have previously reported (31), but primarily located in the cytosol of hepatocytes in HDIL-2 treated animals with an HMGB1 staining void within nuclei. Combination of CQ prevented HMGB1 translocation (Figure 2A). This result is consistent with the change of HMGB1 serum levels in mice under different treatments. When compared with sham animals, tumor injection temporarily increases serum HMGB1 levels within 24 h following tumor intraportal delivery which then returns to normal levels (31). When compared with the UT control group, serum HMGB1 levels were significantly increased in animals receiving HD IL-2 treatment (p<0.05) (Figure 2B). Conversely, combinations of CQ with IL-2
significantly decreased HMGB1 serum levels when compared with HDIL-2 alone (p<0.05). These results suggest that CQ may limit HDIL-2 induced HMGB1 release thereby decreasing the associated systemic toxicity. CQ administration alone did not change the serum levels of HMGB1.

Similar results were observed with other inflammatory cytokines. Compared with untreated control, HDIL-2 significantly increased levels of IL-6, IL-18 and IFN-γ in the serum. Administration of CQ inhibited levels of all cytokines except IL-18, which increased slightly. Thus the “cytokine storm” associated with the systemic toxicity of HDIL-2 were at least partially inhibited by CQ administration.

**HDIL-2 significantly enhances immune cell proliferation and infiltration within the liver and spleen.**

Two hours following the last dose of HDIL-2 injection twice daily for five days, liver non-parenchymal cells and splenocytes were isolated, counted and analyzed by flow cytometry. Consistent with our previous study, intrahepatic leukocyte numbers and splenocyte numbers were not changed following intraportal infusion of MC38 tumor cells (31) but significantly increased by administration of HDIL-2. Flow cytometric analysis suggested that HDIL-2 significantly increased CD11c⁺, CD4⁺, CD8⁺, and CD11b⁺ cells (Figure 3A, p<0.004). Combination of IL-2 and CQ further enhanced this effect. There was also a modest elevation of Gr-1⁺/CD11b⁺ cells and CD4⁺/CD25⁺ cells as well as CD8+ cells (p<0.05, Figure 3B).

**HDIL-2 administration induces profound mitochondrial changes and heightened autophagy.**

To assess the systemic effects of HDIL-2, (1.5x10⁶ IU IL2 BID) was administered and liver and kidney tissues from individual groups of mice were harvested and processed for TEM. When compared with UT animals, hepatocyte mitochondria from IL-2 treated mice had disrupted outer mitochondrial membranes and absent or disordered mitochondrial cristae. This could be a consequence of membrane provision to rapidly generate autophagosomes as has been reported in the setting of starvation (34) or a reaction to toxic reactive
oxygen species generated during IL-2 induced stress. Increased endoplasmic reticulum (ER) surrounding the altered mitochondria were also visualized. The ultrastructure of the kidney proximal and distal tubule cells from both control and treated mice appeared normal (Figure 4A). Furthermore, liver and kidney tissue lysates were collected from tumor bearing mice that received IL-2 alone or in combination with CQ on the day following the last dose of IL-2. HDIL-2 treatment increased the apparent level of autophagic flux with enhanced conversion of LC3-I to LC3-II in the liver but not within the kidney tissue lysates, suggesting resistance of some tissues to the induction of autophagy. CQ blocks the formation of autolysosomes, inhibiting the final steps of the autophagic process (35). Administration of CQ further enhances LC3-I/II levels in both groups of mice receiving CQ alone or in combination with IL-2. Enhancement of visualized autophagic vacuoles (termed autophagosomes) in treated animals were not observed (Figure 4B).

Chloroquine inhibits autophagic flux in tumor cells.

To determine whether CQ causes a similar effect on tumor cells, LC3 punctae were assessed in both MC38 and Panc02 cells. When compared with the untreated controls, CQ-treated tumor cells exhibited intense LC3 punctae by immunofluorescent staining (Figure 5A). Under TEM, tumor cells appeared to have lost visible mitochondria and rough endoplasmic reticulum while accumulating autophagic vacuoles (AV) within the cytosol (Figure 5B). To confirm these immune-cytochemical observations, western blots were performed on whole cell lysates collected at 4 h following treatment with either 100 or 200 μM CQ and the level of LC3-I and LC3-II assessed. A dose dependent increase of LC3-II was observed in both MC38 and Panc02 cells (Figure 5C). These results suggest that CQ induces accumulation of AV, inhibiting autophagic flux in both tumor cell lines.

Chloroquine treatment alters tumor cell metabolism

With TEM, in addition to accumulated AVs, we also found altered mitochondria which have disrupted outer membrane and disordered
mitochondrial cristae (arrow) in CQ-treated tumor cells (Supplemental Figure 4). This suggested that CQ may alter tumor cell metabolism. Cells synthesize ATP solely through two pathways, mitochondrial respiration (oxidative phosphorylation, OXPHOS) and glycolysis. OXPHOS is more efficient, accounting for 90% of the ATP synthesized within normal cells. According to the Warburg hypothesis (36), tumor cells are surprisingly more dependent on glycolysis even in the presence of adequate oxygen and nutrients. In ATP production studies, blockade of glycolysis with 2-DG in MC38 and Panc02 tumor cells significantly diminished ATP levels but did not change when OXPHOS was blocked by oligomycin and rotenone (Supplemental Figure 5) This has been attributed to both the need for substrate for anabolism and cell division (37) as well as the requirement of more rapid ATP generation by glycolysis in the setting of cell stress.

To demonstrate that CQ alters tumor cell metabolism, an XF bioenergetic assay system was employed to explore the effects of CQ treatment on the bioenergetic phenotype of MC38 tumor cells by real-time monitoring of mitochondrial respiration in which oxidative phosphorylation (OXPHOS) is measured by oxygen consumption rate (OCR) while glycolysis is measured by the generation of lactate and the consequent extracellular acidification rate (ECAR). MC38 cells were exposed to 100 μM CQ for 4 hr after which the effects of successive addition of oligomycin, FCCP, 2-Deoxy-D-glucose (2-DG), and rotenone, OXPHOS and glycolysis rates were measured in real time. CQ significantly decreased baseline OCR in a dose-dependent fashion (Figure 6A, B) but had no effect on baseline ECAR (data not shown). The addition of the Complex V inhibitor, oligomycin, resulted in similar decrease in OCR with or without CQ addition. The mitochondrial uncoupler, FCCP, restored OXPHOS to levels above the baseline. 2-DG is a glucose analog that inhibits hexokinase, the first enzyme in the glycolysis pathway, converting glucose to glucose-6-phosphate. Blockade of glycolysis by addition of 2-DG raised OCR slightly within control tumor cells because of OXPHOS compensation while the presence of CQ inhibited this effect. Addition of the Complex I inhibitor rotenone significantly decreased both OCR and ECAR. These studies demonstrate that CQ decreases
both OXPHOS and glycolysis within MC38 tumor cells, promoting a metabolic death. The agent ethyl pyruvate, which we have shown has antitumor activity and limits HMGB1 release, increased oxidative phosphorylation (Supplemental Figure 6), suggesting that the OXPHOS decrease is not a generalizable phenomenon attributable to antitumor compounds.

As OXPHOS and glycolysis constitute the sole energy source of tumor cells, ATP levels were measured in the presence or absence of chloroquine. We found that ATP levels were markedly diminished following a short term increase that may have resulted from compensatory increases in OXPHOS (Figure 6C).

**Chloroquine treatment induces tumor cell apoptosis.**

CQ directly inhibits CT26 proliferation by inducing apoptosis both in vitro and in vivo (24). We demonstrated that CQ inhibits MC38 and Panc02 cell proliferation and survival. The role of autophagy in tumor cell survival has not been elucidated completely, and the relationship between autophagy and apoptosis is complex, but in general, they are regulated reciprocally, with inhibitors of autophagy promoting apoptosis, perhaps by modulating mitochondrial pathways or mitophagy. Our findings indicate that CQ inhibits MC38 tumor cell autophagy. This effect may be related to induction of tumor cell apoptosis, given the complex interaction between the two processes. Addition of CQ to MC38 cells induced a significant dose-dependent increase in apoptotic cells, as demonstrated by Annexin V staining (Figure 7A). Increased cleaved caspase-3 and cleaved PARP production were found by western blotting (Figure 7B). Enhanced release of cytochrome C into the cytosol in CQ treated tumor cells was also observed by both western blot and immuno-fluorescent staining (Figures 7C and D). In aggregate, autophagy inhibition is indeed associated with induction of apoptosis in these cells.
Discussion

In the development of modern immunotherapy, experimentation in animal models has played an important role in advancing clinical trials in patients (38). Interestingly, the first murine tumor models used to demonstrate potent anti-tumor activity of IL-2 were methylcholanthrene-induced sarcomas with essentially no antitumor activity in humans with sarcomas. Similarly, although renal cancer and melanoma are the primary targets in humans, murine models show low activity of IL-2 alone in the Renca tumor model (although improved with the addition of IL-12 or IL-18) and with the nonimmunogenic murine melanoma, B16. It is perhaps best to consider, for many of these long-term cultured tumors, that the most important measure is of intrinsic immunogenicity rather than the tissue of origin. The liver is the primary site for metastasis in many epithelial tumors and, when unresectable, is associated with a high mortality rate. An hepatic model seems to more closely emulate metastases when compared with subcutaneous metastasis models (31). In this study, we established a reliable hepatic metastatic colorectal cancer model in mice using the intraportal route for injection. Using luciferase-labeled MC38 cells, enhanced tracking and better visualization of tumor growth is noted, allowing excellent correlation with data from pathologic examination and gross measurement of tumor bulk. This animal model permits sensitive detection and follow-up of hepatic metastases in vivo, allowing us to observe long term anti-tumor effects of HDIL-2 immunotherapy and perform mechanistic studies.

Although the precise mechanism(s) by which IL-2 mediates its anticancer effects is not fully understood, it is largely believed that it is affected by enhanced delivery to and activation of cytolytic effectors within tumor sites. Notwithstanding the presence of immune effectors, effective elimination of cancer often does not ensue, and the resistance has largely been attributed to effector dysfunction mediated by “exhaustion” (39) or the suppressive influences mediated by T regulatory cells (40) or myeloid derived suppressor cells (41). We have demonstrated that one of the major mechanisms of resistance resides in the target cells’ enhanced autophagy and resistance to apoptosis (42). Here we
reported that administration of the autophagy inhibitor, CQ promotes substantial long-term antitumor effects when coupled with administration of IL-2. We also showed that IL-2 administration, in addition, causes not only release of HMGB1, a potent inducer of endogenous (33) and exogenous (43) autophagy, but also electron micrographic changes consistent with enhanced autophagy.

As a prototypic Damage Associated Molecular Pattern (DAMP) molecule, HMGB1 plays a central role in the pathogenesis of many inflammatory states released following tissue damage or injury, and is found in the serum including cancer (38-42) as well as other settings. In this model, we found that HMGB1 was released following HDIL-2 treatment and levels in the serum decreased following CQ treatment. We consider HMGB1 to be a likely candidate factor promoting the development of the ‘systemic autophagic syndrome’.

CQ has been used for over half a century in humans for the treatment of rheumatoid arthritis, SLE, HIV and malaria. CQ inhibits autophagy by blocking acidification of the lysosome, preventing fusion with the autophagosome (23). In a stressed cell, dependent on autophagy, this last step blockage results in increased generation of autophagosomes, eventually undergoing either apoptotic or necrotic cell death. Recently, several studies have shown that CQ has extensive biological effects, inhibiting cellular proliferation and/or inducing apoptosis in human and murine tumor cell lines such as the erythroleukemia K562 cells, breast cancer Bcap-37 cells (44), lung cancer A549 cells (27), ductal pancreatic adenocarcinoma cells, melanoma cells, C6 glioma cells (35), and mouse 4T1 cells. Autophagy inhibitors by themselves are unlikely to have significant clinical benefit, since only a small fraction of the tumor cells are under metabolic stress at a given time point. When combined with other chemotherapy agents, CQ enhanced cisplatin’s cytotoxic effect and induced apoptosis by increasing the levels of intracellular misfolded proteins. In human cancer cell lines (24, 29) and murine models (30), CQ may exert significant antitumor activity by inhibiting the induction of autophagy following cancer therapy. CQ enhances chemotherapy and radiation sensitivity in clinical trials, the potential mechanisms underlying this enhancement are still unclear (45). Although Noman et al (20)
have recently shown that CQ administration promotes the effectiveness of antitumor vaccines in a murine model, ours is the first demonstration that it enhances the effectiveness of a cytokine therapy. Here we also show that CQ limits autophagic vesicle degradation \textit{in vitro} in two murine tumor cell lines. (Figure 5).

We demonstrated that CQ not only limited autophagy but also enhanced tumor cell apoptosis (Figure 7). Induction of apoptosis was associated with the loss of mitochondrial membrane potential, release of cytochrome c, and activation of caspase-9 and caspase-3, and cleavage of poly(ADP-ribose) polymerase. \textit{In vivo}, CQ significantly inhibited 4T1 tumor growth and metastasis in murine models and induced apoptosis in the tumor microenvironment (28). Autophagy also plays an important role in the effector-target interactions of cytotoxic cells and can confer a survival advantage for tumor cells targeted for cytotoxic cell killing. Autophagy may contribute to tumor resistance and perhaps to the toxicity observed during IL-2 cancer therapy (46). Our results suggest that inhibition of autophagy with CQ in combination with HDIL-2 treatment can increase the antitumor effects and increase survival when compared with IL-2 treatment alone.

Several studies have suggested that autophagy may act as a protective mechanism in tumor cells in which cell death is induced by drugs, and that inhibition of autophagy provides antitumor effects alone (22-24) or synergistic effect with such drugs (25). The role of metabolism in cancer is increasingly being appreciated (47). With the notion that conventional oxidative phosphorylation is suppressed, replenishing anapleurotic production of Krebs cycle substrates, enabling anabolism, and cell division is necessary in stressed cells. Enhanced autophagy promotes degradation of intracellular substrates and allows generation of amino acids, nucleotides, and lipids that can promote and enable subsequent replication. Here we show that CQ (but not ethyl pyruvate) has the additional role of diminishing oxidative phosphorylation and limiting ATP production. This too may be part of the mechanism important in enhancing susceptibility in combination with IL-2 therapy.
Further work must evaluate the precise immunologic mechanisms operative in the IL-2 and CQ combination (Supplemental Figure 7), defining which immune effectors (T-cells or NK cells or both) have their activity promoted, whether autphagic inhibition limits immune reactivity through effects on dendritic cells, and define the precise role of HMGB1 in some of the biologic changes that we have demonstrated. To that end, we recently created floxed HMGB1 mice and are testing its elimination in pancreas, DCs, and NK cells. Recent studies (48) suggest that autophagy is required for the immunogenic release of ATP from dying tumor cells, and increased extracellular ATP release improves the efficacy of chemotherapy when autophagy is disabled. Further understanding of the complex biologic roles of metabolism, autophagy, and immune effectors will allow development of more effective and less toxic regimens for patients with cancer. We have initiated a clinical protocol to test the delivery of IL-2 with the CQ congener hydroxychloroquine in patients with advanced renal cell cancer based on these findings.

Acknowledgements

We would like to acknowledge Prometheus for the kind gift of IL-2. Dan Normolle in UPCI biostatistics was consulted for statistical and power considerations. We would like to give special thanks to our Cancer Center director, Nancy Davidson and the Department of Surgery Chairman, Timothy Billiar for supporting this work. The work was also supported by NIH P01 (CA 101944-04) and NCI core support P30CA047904.
References:


Table 1. Combination CQ With HDIL-2 Prolongs Survival Time.

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Survival time (day)</th>
<th>Median survival time</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>10</td>
<td>27X3, 30, 31, 37, 38X2,40, 55</td>
<td>31</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>9</td>
<td>27, 31, 33, 34, 38X2, 42X2, 70</td>
<td>38</td>
</tr>
<tr>
<td>rIL-2 60K IU</td>
<td>5</td>
<td>31, 33, 38, 66, &gt;150</td>
<td>38</td>
</tr>
<tr>
<td>rIL-2 60K IU+CQ</td>
<td>5</td>
<td>32, 38, 43, 68, 114</td>
<td>43 *</td>
</tr>
<tr>
<td>rIL-2 600K IU</td>
<td>9</td>
<td>50, 53, 55, 107, 135, &gt;150x4</td>
<td>135**</td>
</tr>
<tr>
<td>rIL-2 600K IU +CQ</td>
<td>10</td>
<td>66, &gt;150x9</td>
<td>150 **</td>
</tr>
</tbody>
</table>

Compare with PBS control group: * : p<0.05, ** p<0.001
Compare with rIL-2 600KIU alone: p=0.02
Figure Legends:

Figure 1. Chloroquine combination with rIL-2 markedly enhances anti-tumor effects, prolonging survival time in a murine hepatic metastasis model. C57BL/6 mice received 2X10⁵/mouse luciferase expressing MC38 tumor cell via portal vein injection. On day 7 following tumor implantation, after an initial bioluminescence (BLI) measurement, mice were randomly divided into 6 groups and treated. Tumor growth was measured by BLI weekly and presented as the intensity of the luciferase signal. (A) BLI signals represents tumor development in individual animals (n=5/group) before (week 1, first row) and after treatment (week 2,3 and 4). Results shown are representative of three experiments. (B) Regions of interest were manually selected and quantification is reported as the average of photon flux within regions of interest. Each curve represents tumor development in a single mouse. Results shown are representative of three experiments. (C) Body weights were recorded every other day before and during treatment. The gains of body weight are compared with the body weight on the day before treatment. Each curve represents gain of body weight in individual mice. Administration of CQ prevents the gain of body weight in IL-2 treated mice (p<0.05) (D).Murine survival curve. When compared with the normal saline (untreated control, UT ) group, HDIL-2 alone markedly prolonged survival time (p<0.01). CQ significantly enhanced HDIL-2 antitumor effects (p=0.024).

Figure 2. CQ decreases HMGB1 release that is stimulated by administration of IL-2. On day 12 following tumor cell inoculation, two hours after the last dose of IL-2 injection 3 mice from each group were sacrificed, livers and serum were harvested. (A) Immunofluorescence staining was performed using rat anti-human HMGB1 antibody (red) and DAPI nuclear staining (blue). HDIL-2 induced HMGB1 translocation from the nucleus into the cytoplasm in hepatocytes (arrow). HMGB1 was restricted in the nucleus with combination of CQ. Image represents 2 independent experiments using samples isolated from four individual mice. (B) Serum HMGB1 levels and (C) IL-6, IL-18 and IFN-γ were measured by ELISA and diminished after CQ administration (except IL-18). Results shown are representative of two independent experiments.
Figure 3. Administration of HDIL-2 and CQ stimulated immune cells proliferate and infiltrate into liver and spleen. Mononuclear cells from (A) livers and (B) spleens (3 mice/group) were isolated. Cell number were counted and normalized by tissue weight. Cells were stained with individual antibodies and analyzed by flow cytometry. Data shown are representative of one of three similar experiments performed. ANOVA p-values are shown for each set.

Figure 4. HDIL-2 administration promotes mitochondrial swelling and morphologic changes as well as autophagy in vivo. (A) Livers and kidneys were harvested from mice which received HDIL-2 (bottom row) treatment or UT (upper row) as a control. Ultrastructure of liver and kidney were observed under transmission electron microscopy (TEM). Damaged mitochondrial which exhibit plasma membrane disruption, absent and disordered mitochondrial cristae (arrow) are observed in hepatocytes from IL-2 treated mice but not in control mice. The ultrastructure of a renal proximal tubule cell from both control and treated mice appear normal. (M indicates mitochondria). (B) Western blot analysis was performed in liver and kidney tissue lysates collected from tumor bearing mice which received IL-2 and/or in combination with CQ on the day after the last dose of IL-2 treatment (day 12). Enhanced autophagic flux was confirmed with increased LC-3 II levels. Numbers below represent LC3-II/actin ratio. Data are representative of one of three experiments.

Figure 5. CQ inhibits autophagy in tumor cells in vitro. MC38 and Panc02 tumor cells were cultured and treated with 100 or 200µM CQ for 4 hour respectively. (A) Immunofluorescence staining was performed for LC3 (green), actin (phalloidin, red) and nuclei (DAPI, blue). CQ increased LC3 punctae in both MC38 and Panc02 cells. (B) Ultrastructure of tumor cells was observed under TEM. An accumulation of autophagosomes (arrow) were observed in chloroquine treated cells. (C) Western blot analysis for LC3-I/II demonstrating a dose-dependent increase in MC38 tumor cells treated with CQ. Numbers shown below the Figure represent LC3-II/actin ratio. Data are representative of three experiments.
Figure 6. CQ alters tumor cell metabolism. (A) Oxygen consumption rate (OCR) was measured in real time in a Seahorse XF bioenergetic assay. 2X10^5 tumor cells were seeded with or without 100μM CQ for 4 hours. (B) Average OCR was calculated from 3 measurements during the treatment of each compound (oligomycin, FCCP, 2-DG, rotenone) at the concentration as indicated. (C) MC38 tumor cells were treated with 100μM CQ for the time indicated. Levels of ATP production were plotted as mean with standard deviations from experimental replicates.

Figure 7. CQ induces tumor cell apoptosis associated with cytochrome C release from mitochondria. Tumor cell were cultured in the presence of 100 or 200 µM CQ for 4 hr or 24 hr before harvest. (A) Tumor cells exposed to 100 µM CQ for 4 hr and stained with Annexin V/PI were analyzed by flow cytometry. (B) Western blot analysis for cleaved PARP (C-PARP), cleaved caspase-3 demonstrating a dose-dependent increase in apoptosis of MC38 and Panc02 tumor cells treated with CQ. Numbers presented below each figure represent cleaved caspase 3/actin or cleaved PARP/actin ratio. Results shown are representative of three experiments. (C) Protein from mitochondria and cytosol of CQ treated MC38 cells were analyzed for cytochrome C by western blot analysis which demonstrated the release of cytochrome C from mitochondria into cytosol. Cells untreated or under serum starvation were used as controls. Numbers presented below each represent Cyt C/actin ratios. Results shown are representative of one of three experiments. (D) MC38 cells were treated with 100µM CQ for 24 hours then stained with cytochrome C (green), TOM-20 (mitochondrial marker, red) and Hoechst (blue). CQ treatment increases cytochrome C release.
Figure 2

(A) Immunofluorescence images showing the localization of HMGB1, DAPI, and Merge in cells treated with different conditions. (B) Bar graph showing the serum levels of HMGB1 in UT, CQ, IL-2, and IL-2+CQ conditions. The statistical significance is indicated as p<0.05. (C) Bar graph showing the serum levels of IL-18, IFN-γ, and IL-6 in UT, CQ, IL-2, IL-2+CQ conditions. The statistical significance is indicated as p<0.001, p<0.01, and ns (not significant).
Figure 3

A

Overall

p<0.001

CD11c

p<0.001

CD8

p<0.001

CD4

p<0.001

NPC

NKp46

ns

CD11b

p=0.004

Gr-1/CD11b

ns

CD4/CD25

ns

Fold Change in Abs Cell Number (x 10^6/g tissue)

B

Overall

ns

CD11c

ns

CD8

p<0.001

CD4

ns

SPL

NKp46

ns

CD11b

ns

Gr-1/CD11b

ns

CD4/CD25

p=0.016

Downloaded from cancerres.aacrjournals.org on July 20, 2017. © 2012 American Association for Cancer Research.
Figure 4

A

<table>
<thead>
<tr>
<th></th>
<th>Liver</th>
<th>Kidney</th>
</tr>
</thead>
<tbody>
<tr>
<td>UT</td>
<td>![Liver UT]</td>
<td>![Kidney UT]</td>
</tr>
<tr>
<td>IL-2</td>
<td>![Liver IL-2]</td>
<td>![Kidney IL-2]</td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th></th>
<th>Tumor</th>
<th>CQ</th>
<th>IL-2</th>
<th>LC3-I</th>
<th>LC3-II</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>19 KD</th>
<th>17 KD</th>
<th>42 KD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.30</td>
<td>0.24</td>
<td>0.54</td>
</tr>
<tr>
<td></td>
<td>0.45</td>
<td>0.66</td>
<td>0.92</td>
</tr>
<tr>
<td></td>
<td>1.07</td>
<td>0.59</td>
<td>0.19</td>
</tr>
</tbody>
</table>
Figure 5

A  CQ (µM)  0  100

B  CQ (µM)  0  100  200

C  Serum starvation - - - + + +
   LC3-I - - - + + +
   LC3-II - - - + + +
   β-actin - - - + + +

MC38
Panc02

19 KD
17 KD

0.38 0.55 0.77 0.60 0.73 0.58
0.48 0.55 0.63 0.58 0.61 0.59
Figure 7

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z
Inhibiting Autophagy During Interleukin 2 Immunotherapy Promotes Long Term Tumor Regression

Xiaoyan Liang, Michael E de Vera, William J. Buchser, et al.

Cancer Res  Published OnlineFirst April 3, 2012.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-12-0320

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2012/04/02/0008-5472.CAN-12-0320.DC1

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.